II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen. Am J Physiol Regul Integr Comp Physiol 296: R1376 -R1384, 2009. First published February 18, 2009 doi:10.1152/ajpregu.90962.2008.-ANG II AT1 receptor blockade reduces inflammation in hypertension. To determine whether ANG II AT1 receptor blockers (ARBs) influence the innate immune inflammatory response in normotensive rats, we studied rat plasma and spleen after a 3-day subcutaneous pretreatment with the ARB candesartan followed by a single dose of the bacterial endotoxin LPS (50 g/kg ip). Peripheral administration of LPS to rodents produced a generalized inflammatory response with increased release of TNF-␣, IL-1␤, and IL-6 into the circulation. Candesartan pretreatment reduced the LPS-induced release of TNF-␣, IL-1␤, and IL-6 into the circulation. The red pulp of rat spleen expressed large numbers of AT1 receptors and the LPS receptors Toll-like receptor 4 and CD14. Candesartan administration significantly blocked AT1 receptors. The ARB reduced the LPS-induced upregulation of CD14 gene expression; expression of TNF-␣ and IL-6 mRNA and protein; expression of IL-1␤ and IB-␣ mRNA; COX-2 mRNA and protein expression and PGE2 concentration; inducible nitric oxide synthase (iNOS) gene and protein expression and iNOS activity; and Nox2 gene expression and 8-isoprostane levels. In addition, candesartan reduced the CD14 protein expression in saline-and LPS-treated rats. Our results suggest that AT 1 receptors are essential for the development of the full innate immune response to bacterial endotoxin. The ARB decreased the general peripheral inflammatory reaction to LPS and partially decreased the inflammatory response in the spleen. An unrestricted innate immune response to the bacterial endotoxin may have deleterious effects for the organism and may lead to development of chronic inflammatory disease. We postulate that ARBs may have therapeutic effects on inflammatory conditions. CD14; cyclooxygenase-2; NAPDH oxidase; inducible nitric oxide synthase; proinflammatory cytokines IN ADDITION TO ITS ROLE in the regulation of blood pressure (32), ANG II, the active principle of the renin-angiotensin system (RAS), promotes blood vessel inflammation and endothelial dysfunction in hypertension and atherosclerosis through stimulation of its AT 1 receptor. AT 1 receptor stimulation involves enhanced oxidative stress, transcription factor activation, and cross talk with inflammatory mediators (9, 43-45, 54, 61); AT 1 receptor blockers (ARBs), effective antihypertensive drugs, reverse the chronic inflammatory reaction associated with hypertension by mechanisms unrelated to blood pressure decrease (2, 10, 40, 44, 62) .
To determine whether ANG II AT1 receptor blockers (ARBs) influence the innate immune inflammatory response in normotensive rats, we studied rat plasma and spleen after a 3-day subcutaneous pretreatment with the ARB candesartan followed by a single dose of the bacterial endotoxin LPS (50 g/kg ip). Peripheral administration of LPS to rodents produced a generalized inflammatory response with increased release of TNF-␣, IL-1␤, and IL-6 into the circulation. Candesartan pretreatment reduced the LPS-induced release of TNF-␣, IL-1␤, and IL-6 into the circulation. The red pulp of rat spleen expressed large numbers of AT1 receptors and the LPS receptors Toll-like receptor 4 and CD14. Candesartan administration significantly blocked AT1 receptors. The ARB reduced the LPS-induced upregulation of CD14 gene expression; expression of TNF-␣ and IL-6 mRNA and protein; expression of IL-1␤ and IB-␣ mRNA; COX-2 mRNA and protein expression and PGE2 concentration; inducible nitric oxide synthase (iNOS) gene and protein expression and iNOS activity; and Nox2 gene expression and 8-isoprostane levels. In addition, candesartan reduced the CD14 protein expression in saline-and LPS-treated rats. Our results suggest that AT 1 receptors are essential for the development of the full innate immune response to bacterial endotoxin. The ARB decreased the general peripheral inflammatory reaction to LPS and partially decreased the inflammatory response in the spleen. An unrestricted innate immune response to the bacterial endotoxin may have deleterious effects for the organism and may lead to development of chronic inflammatory disease. We postulate that ARBs may have therapeutic effects on inflammatory conditions. CD14; cyclooxygenase-2; NAPDH oxidase; inducible nitric oxide synthase; proinflammatory cytokines IN ADDITION TO ITS ROLE in the regulation of blood pressure (32) , ANG II, the active principle of the renin-angiotensin system (RAS), promotes blood vessel inflammation and endothelial dysfunction in hypertension and atherosclerosis through stimulation of its AT 1 receptor. AT 1 receptor stimulation involves enhanced oxidative stress, transcription factor activation, and cross talk with inflammatory mediators (9, 43-45, 54, 61) ; AT 1 receptor blockers (ARBs), effective antihypertensive drugs, reverse the chronic inflammatory reaction associated with hypertension by mechanisms unrelated to blood pressure decrease (2, 10, 40, 44, 62) .
Hypertension and atherosclerosis are not the only proinflammatory effects of ANG II. The role of ANG II in the regulation of inflammatory responses was established early during evolution and precedes its participation in cardiovascular control. In invertebrates, ANG II regulates the innate immune response, the initial inflammatory response to infection (38) . As a first step, the innate immune system recognizes specific microbial molecules, including the endotoxin LPS, a major component of the outer membranes of gram-negative bacteria (1, 5) . Recognition of LPS requires its binding to CD14, a membrane-linked receptor, and its association with the Toll-like receptor 4 (TLR4) (46) . This leads to activation of transcription factors, such as NF-B, and stimulation of multiple proinflammatory genes (16, 45) .
ANG II and LPS promote inflammation, activating similar transcriptional and posttranscriptional mechanisms interrelated in complex intracellular cross-talk mechanisms. These include 1) activation of phospholipase C and protein kinase C, leading to NAD(P)H oxidase stimulation and enhanced reactive oxygen species (ROS) formation; 2) activation of transcription factors, such as NF-B, and production of proinflammatory cytokines; 3) cyclooxygenase-2 (COX-2) activation with enhanced proinflammatory prostaglandin E 2 (PGE 2 ) formation; and 4) inducible nitric oxide synthase (iNOS) induction with increased nitric oxide production (11, 13-15, 20, 25, 26, 29, 48, 56) .
The main cellular targets for LPS are endothelial cells lining the vasculature and macrophages, including those concentrated in the spleen (16, 18, 52, 58) . These cells express complete local RAS, including AT 1 receptors (21, 33, 51, 63) . These observations suggest that stimulation of AT 1 receptors is a crucial factor in the macrophage-endothelial cell link at the early stages of the innate immune response (24) . However, this hypothesis and the mechanisms of the proposed ANG II-LPS interaction are controversial (41, 47) . Although some reports support the notion that RAS blockade reduces the LPS-induced inflammation (28, 39, 57) , some others found that RAS blockade does not change, or even enhances, the LPS response (34, 55) . We recently demonstrated that the ARB candesartan significantly reduces the inflammatory response to LPS in the adrenal gland, decreasing not only the expression of some of the LPS-induced proinflammatory factors, but also the LPSstimulated production and release of the proinflammatory hormone aldosterone (39) .
We initiated our studies to determine whether ARBs might be considered of therapeutic interest in inflammatory conditions independently of their blood pressure-lowering effect.
Our initial aim was to determine whether AT 1 receptor activation is necessary for development of a complete innate immune response following administration of systemic LPS. We treated normotensive rats previously given the ARB candesartan with a dose of LPS sufficient to elicit a significant response without the risk of endotoxic shock. To characterize the innate immune response, we studied the secretion of proinflammatory cytokines and formation of PGE 2 in the circulation. We chose to study the spleen, an organ crucial for the innate and adaptive responses to inflammation (3, 8, 36, 58) . We characterized the LPS-mediated reaction and the effect of AT 1 receptor blockade in the rat spleen by studying AT 1 and LPS receptors and key components of the innate immune response. Rats (n ϭ 32) were equally divided into two groups and were injected with vehicle or candesartan (1 mg⅐kg Ϫ1 ⅐day Ϫ1 sc; Astra-Zeneca, Molndal, Sweden) at 0900 for 3 consecutive days. Candesartan was dissolved in 0.1 N sodium carbonate and further diluted in isotonic saline at a final pH of 7.5-8.0. On day 3 starting at 1000, experimental animals from vehicle (n ϭ 9) and candesartan (n ϭ 9) groups were injected with LPS (50 g/kg ip; Escherichia coli serotype 055:B5, Sigma, St. Louis, MO). The rest of animals from vehicle (n ϭ 7) and candesartan (n ϭ 7) groups were injected with sterile saline. At 3 h after LPS or saline injection, the animals were killed by fast decapitation. Trunk blood was collected into polyethylene tubes with EDTA (1 mg/ml blood). Blood was immediately centrifuged at 1,800 g for 15 min at 4°C, and the plasma was stored at Ϫ80°C. Spleens were dissected, snap frozen in cold isopentane, and stored at Ϫ80°C. We determined intra-arterial blood pressures in separate groups of five rats each, injected with vehicle-saline, candesartan-saline, vehicle-LPS, or candesartan-LPS (see above) 2 h after LPS administration.
MATERIALS AND METHODS

Animals
Measurement of intra-arterial blood pressure. A catheter was inserted into the right femoral artery and connected to a pressure transducer for measurement of intra-arterial blood pressure, as described elsewhere (39) . Catheters were flushed with 500 l of 300 IU/ml sodium heparin (APP, Schaumburg, IL) immediately after surgery between 0900 and 1200, a second time at 1900, and a third time at 0900 on the following day. Starting on the day before surgery, candesartan (1 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 ) or vehicle was injected for 3 consecutive days. Immediately after the last dose of ARB or vehicle, rats were injected with LPS (50 g/kg) or sterile saline. Mean arterial blood pressure was recorded with an intra-arterial interface (SC1000IA, Hatteras Instruments, Cary, NC) 2 h later. Measurements were recorded for 1 continuous min, and the average was registered. Animals were awake and undisturbed during the procedure.
ANG II receptor binding. For receptor autoradiography, 16-mthick spleen sections were cut in a cryostat at Ϫ20°C, processed as described elsewhere (50) (50) . The binding to AT 1 and AT2 receptors was the binding displaced by losartan and PD123319, respectively (50) . After incubation, slides were processed as described elsewhere (50), and optical densities of autoradiograms were analyzed by computerized densitometry using Scion Image 4.0.2 (Scion, Frederick, MD) based on the NIH Image program (27, 31) .
ELISA. TNF-␣ and IL-6 concentrations in rat plasma and spleen were measured by rat TNF-␣ and IL-6 ELISA kits (Biosource, Camarillo, CA) according to the manufacturer's protocol. IL-1␤ concentrations in rat plasma and spleen were measured by a rat IL-1␤ ELISA kit (R & D Systems, Minneapolis, MN) according to the manufacturer's protocol. Tyrosine nitration (nitrotyrosine) and 8-isoprostane were measured in rat spleen by a nitrotyrosine ELISA kit (Millipore, Bedford, MA) and an 8-isoprostane enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI), respectively, according to the manufacturers' protocol. PGE 2 was measured in rat plasma and spleen by a PGE 2 ELISA kit (R & D Systems) according to the manufacturer's protocol.
Measurement of mRNA expression by real-time PCR. Total RNA was isolated individually from the homogenized rat spleen using TRIzol (Invitrogen, Carlsbad, CA), purified using an RNeasy Mini kit (Qiagen, Valencia, CA), and treated with DNase I (Invitrogen) according to the manufacturer's instructions. cDNA was synthesized by reverse transcription of 2 g of total RNA using the SuperScript III First-Strand Synthesis kit (Invitrogen) in a total volume of 20 l according to the manufacturer's instructions. Quantitative real-time PCR was performed on DNA Engine Opticon (MJ Research, 
COX, cyclooxygenase; iNOS, inducible nitric oxide synthase; TLR4, Tolllike receptor 4.
Waltham, MA) using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). PCR was performed in a 20-l reaction mixture containing 10 l of SYBR Green PCR Master Mix, 2 l of cDNA, and primer for a specific target at 0.3 M each. The primers were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/ primer3/primer3_www.cgi) as described elsewhere (37) and are listed in Table 1 . The amplification conditions consisted of one denaturation-activation cycle at 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and at 56 or 60°C for 60 s. Serial dilutions of cDNA from the same source as samples were used to obtain a calibration curve. The individual targets for each sample were quantified by determination of the cycle threshold (C t) and by use of calibration curves. At the end of amplification, the specificity of the PCR was confirmed by melting temperature determination of the PCR product. The relative amount of the target was normalized with the housekeeping gene 18S rRNA and expressed as arbitrary units. The expression of the housekeeping gene was not altered by any of the treatments (results not shown).
Western blot analysis. Spleen samples were homogenized in RIPA buffer (1:10 wt/vol) supplemented with 10% glycerol, 1 mM dithiothreitol, 5 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium fluoride, and protease inhibitor cocktail (Complete Mini, Roche Applied Science, Indianapolis, IN). The homogenates were centrifuged for 15 min at 14,000 g at 4°C, and supernatants were saved and stored at Ϫ80°C until further processing. Protein concentration was measured by a commercial bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Samples containing ϳ20 g of proteins were electrophoresed on 10% or 4 -12% Nupage Novex Bis-Tris Midi Gel (Invitrogen) and then transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA). The membranes were blocked with 1ϫ blocking buffer (Sigma) at room temperature for 60 min and then probed with the primary antibodies overnight at 4°C. After they were washed with Tris-buffered saline [10 mM Tris-Cl (pH 7.5) and 100 mM NaCl] containing 0.1% Tween 20, the membranes were incubated with horseradish peroxidase-conjugated goat anti-mouse (1: 10,000 -20,000 dilution; Jackson ImmunoResearch Laboratories, West Grove, PA) or donkey anti-rabbit IgG (1:2,000 -5,000 dilution; GE Healthcare, Little Chalfont, UK) for 120 min at room temperature. The proteins were visualized by the SuperSignal chemiluminescent substrates (Pierce, Rockford, IL) and detected by exposure to Kodak XAR film. The intensity of each band was quantified by densitometry using Scion Image software. ␤-Actin monoclonal antibody (1:10,000 dilution; Sigma) was used as a sample loading control. Statistical analysis. Values are means Ϯ SE for groups of seven to nine animals measured individually. Statistical differences were determined by using one-way ANOVA followed by the multiple comparisons Newman-Keuls test. P Ͻ 0.05 was considered statistically significant. All statistics were performed with Prism 3.03 software (GraphPad Software for Science, San Diego, CA).
RESULTS
Effects of AT 1 receptor blockade and LPS administration on blood pressure.
Treatment with the ARB produced a small but significant decrease in mean intra-arterial blood pressure (P Ͻ 0.05 vs. vehicle). There were no significant changes in intra- arterial blood pressure after LPS administration, and the endotoxin did not alter the blood pressure decrease produced by the ARB administration: 116.2 Ϯ 4.9 mmHg with vehicle-saline, 82.6 Ϯ 5.8 mmHg with candesartan-saline, 113.2 Ϯ 5.7 mmHg with vehicle-LPS, and 84.8 Ϯ 9.3 mmHg with candesartan-LPS.
Effects of AT 1 receptor blockade on the LPS-induced increase on circulating levels of proinflammatory cytokines and PGE 2 . The inflammatory cytokines TNF-␣, IL-1␤, and IL-6
were not detectable in the plasma of rats treated with saline, with or without pretreatment with candesartan ( Fig. 1) . LPS administration markedly induced release of TNF-␣, IL-1␤, and IL-6 into the circulation (Fig. 1) . Pretreatment with candesartan significantly decreased the LPS-induced release of TNF-␣, IL-1␤, and IL-6 (Fig. 1) .
In saline-treated rats, pretreatment with candesartan significantly decreased plasma levels of PGE 2 (Fig. 1) . LPS administration increased PGE 2 levels in plasma, and this increase was reduced by pretreatment with candesartan ( Fig. 1) .
Effects of AT 1 receptor blockade on the LPS-induced expression of CD14 and TLR4 in the rat spleen.
Administration of LPS markedly induced CD14 mRNA expression in the rat spleen, an effect partially reduced by pretreatment with candesartan (Fig. 2) . LPS did not significantly affect the levels of CD14 protein in the spleen (Fig. 2) . Treatment with candesartan reduced CD14 protein expression in the spleen of rats treated with saline or LPS (Fig. 2) .
Neither LPS nor candesartan treatment modified the expression of TLR4 mRNA or protein in the rat spleen (Fig. 2) .
Effects of candesartan administration on ANG II AT 1 receptors in the rat spleen. The rat spleen expresses large numbers of ANG II AT 1 receptors, localized to the red pulp (Fig. 3A) . No ANG II AT 2 receptor expression was observed in the spleen (Fig. 3A) . The number of AT 1 receptors was not altered after administration of LPS. Candesartan treatment effectively blocked most of the AT 1 receptors in the spleen (Fig. 3B) .
Effects of AT 1 receptor blockade on the LPS-induced expression of proinflammatory cytokines in the rat spleen. LPS administration markedly enhanced expression of TNF-␣, IL-1␤, and IL-6 mRNA and induced expression of TNF-␣, IL-1␤, and IL-6 protein in the rat spleen (Fig. 4) . Pretreatment with candesartan did not change mRNA or protein expression of proinflammatory cytokines in animals treated with saline (Fig.  4) . Pretreatment with candesartan significantly reduced the LPS-induced increase in mRNA expression of all proinflammatory cytokines studied (Fig. 4) and decreased the LPSinduced increase in TNF-␣ and IL-6 protein (Fig. 4) . Administration of candesartan did not change the LPS-induced expression of IL-1␤ protein (Fig. 4) .
Effects of pretreatment with candesartan on the LPS-induced stimulation of the NF-B pathway in the rat spleen.
Administration of LPS enhanced NF-B pathway activity in the rat spleen, as determined by the expression of IB-␣ mRNA (Fig. 5) . Pretreatment with candesartan did not alter basal IB-␣ mRNA expression in rats treated with saline but significantly reduced the LPS-induced increase in IB-␣ mRNA expression (Fig. 5) .
Effect of administration of candesartan on the LPS-induced expression and activity of COX-2. LPS induced expression of COX-2 mRNA and protein and significantly enhanced PGE 2 levels in the rat spleen (Fig. 6) . Pretreatment with candesartan did not change basal levels but markedly decreased the LPSinduced COX-2 mRNA and protein expression and inhibited the LPS-enhanced PGE 2 levels in the rat spleen (Fig. 6) . 
Effect of pretreatment with candesartan on LPS-induced expression and activity of iNOS and nitrotyrosine formation.
Treatment with LPS induced iNOS mRNA and protein expression and iNOS activity in the rat spleen (Fig. 7) . In salinetreated rats, candesartan did not change iNOS mRNA or protein expression or iNOS activity (Fig. 7) . Pretreatment with candesartan significantly reduced the LPS-induced iNOS mRNA expression and iNOS activity but did not modify iNOS protein expression (Fig. 7) .
LPS enhanced spleen levels of nitrotyrosine, an indirect measure of peroxynitrite formation (Fig. 7) . Candesartan did not change basal nitrotyrosine levels in saline-treated rats but significantly decreased LPS-induced increase in nitrotyrosine in the rat spleen (Fig. 7) .
Effect of AT 1 receptor blockade on the LPS-induced expression of Nox2 and ROS production in the spleen. LPS significantly increased the expression of Nox2 mRNA, a catalytic subunit of NAD(P)H oxidase, and the spleen levels of 8-isoprostane, a marker of oxidative stress (Fig. 8) . Candesartan treatment did not significantly modify basal Nox2 mRNA expression or 8-isoprostane levels (Fig. 8) . Pretreatment with candesartan blunted the LPS-induced increase in Nox2 mRNA expression and 8-isoprostane levels in the rat spleen (Fig. 8) .
DISCUSSION
We have demonstrated that administration of an ARB in vivo substantially limits the innate immune response to systemic administration of LPS in normotensive rats. The ARB effects included reduction in LPS-induced secretion of proinflammatory cytokines and decreased protein and/or mRNA expression of inflammatory factors in the spleen. These observations indicate that AT 1 receptor activity is involved in the innate immune response to LPS. This conclusion is further supported by our recent observations of the reduction of the inflammatory response to LPS in the adrenal gland in animals pretreated with the ARB candesartan (39) . Our results support the hypothesis that ARBs are potent anti-inflammatory compounds not only in hypertension (2, 40, 54, 62) , but also in other inflammatory processes (10, 28, 30, 39, 57) .
We have reported that LPS administration does not alter blood pressure. Pretreatment with the ARB produced a small but significant reduction in blood pressure, as reported earlier (39) , to a similar extent in control and LPS-treated animals. Alterations in immune-related factors after ARB administration to rats not injected with LPS were few and limited to decreases in basal CD14 protein expression in the spleen and plasma PGE 2 content. This suggests that minor changes in blood pressure may have, at most, a restricted impact on immunological parameters.
LPS administration produced a generalized peripheral innate immune response in our study as expected (1, 5, 12, 22, 25) . The appearance of high concentrations of proinflammatory cytokines in the circulation indicates activation of transcription factors in LPS-responsive cells such as macrophages and endothelial cells (1, 5, 12, 25) , whereas the LPS-induced increase in circulating PGE 2 may be best interpreted as the result of stimulation of COX-2 activity (17) .
Prior ARB treatment significantly reduced the endotoxin effects. This indicates AT 1 receptor antagonism in macrophages and endothelial cells located in many organs and a major participation of the spleen (35, 52, 58) . We noted that ARB treatment alone significantly reduced PGE 2 levels in the circulation. This suggests that AT 1 receptor activity may be needed for constitutive COX-2 activity in selected cells.
We used a dose of candesartan that had been previously proven to eliminate the increase in blood pressure provoked by ANG II infusion (32) but had resulted in only a minor decrease in blood pressure in normotensive rats (39) . The ARB blocked Fig. 7 . Effects of LPS and AT1 receptor blockade on inducible nitric oxide synthase (iNOS) gene and protein expression, iNOS activity, and nitrotyrosine content in rat spleen. Data correspond to relative levels after normalization to 18S rRNA for mRNA and ␤-actin for protein.
Values are means Ϯ SE of groups of 7-9 rats measured individually. *P Ͻ 0.05; ***P Ͻ 0.001 (1-way ANOVA and post hoc Newman-Keuls test).
spleen AT 1 receptors in vivo and, therefore, blocked the effects of locally formed or circulating ANG II in our experiments. We do not provide evidence of LPS effects on transcription of RAS components in the spleen. However, the LPS dose used here did not alter blood pressure or plasma renin activity in normotensive rats (39) , and the expression of spleen AT 1 receptors was not affected by LPS administration. This suggests that peripheral RAS and local spleen RAS were not upregulated by the subseptic dose of the endotoxin used in our experiments.
We have not examined which cell types of the spleen express AT 1 receptors and whether these cell types are the same as those targeted by LPS. However, AT 1 receptors are highly concentrated in the red pulp of the spleen, an area extremely rich in macrophages, which are typical target sites for LPS (52, 53, 58) . Although our results are indicative of direct effects of LPS on the spleen, we cannot exclude the participation of additional target cells regulating the LPSinduced inflammatory response (1, 5, 12, 25) .
We have shown that ARB treatment significantly reduced the LPS-induced increased transcription of the inflammatory cytokines TNF-␣, IL-1␤, and IL-6 in the spleen, a major target organ for systemic LPS administration (3, 36, 58) . Although the ARB reduced the LPS-induced TNF-␣ and IL-6 protein content in the spleen, it failed to significantly modify the increase in IL-1␤ protein content produced by the endotoxin. The LPS effects on cytokine transcription and translation are time dependent, and we studied expression of cytokine mRNA and protein at a single time point after LPS administration. This could explain the apparent discrepancy between the effects of the ARB on mRNA and protein expression of IL-1␤. The ARB inhibited LPS-induced ROS production, as shown by the decrease in LPS-induced Nox2 transcription and formation of 8-isoprostane, a marker of oxidative stress, confirming recent results (19) . Lack of significant changes in Nox2 protein expression after LPS and ARB administration could also be interpreted as the result of different time-dependent responses of Nox2 transcription and translation, as recently reported (59) . A decrease in the LPS-stimulated COX-2 transcription and activity was revealed by decreased PGE 2 formation, confirming recent reports of COX-2 inhibition by ARBs (39, 47) .
In addition, the ARB prevented the increase in iNOS mRNA produced by LPS, an indication of reduced inflammation (6, 60) . Decreased iNOS activity correlated well with the decrease in LPS-induced protein nitration observed in the spleen after ARB treatment. The ARB did not modify the induction on iNOS protein expression produced by LPS. This apparent contradiction could be best explained by different time courses for transcription, translation, and enzyme activity after administration of LPS (42, 59) .
The cytokines, Nox2, iNOS, and COX-2 inflammatory pathways converge on a set of transcription factors such as NF-B (4, 5, 17) . LPS signaling leads to IB-␣ phosphorylation and degradation, allowing nuclear translocation of NF-B followed by enhanced IB-␣ transcription to balance NF-B effects (10, 53) . Accordingly, the reduction of LPS-induced IB-␣ mRNA expression by the ARB treatment should be interpreted as an inhibition of NF-B activation (10, 53) , the most likely mechanism involved in the limitation of the inflammatory reaction observed here. Our results support the previous hypothesis that NF-B is an important mediator of ANG II inflammatory effects (40, 44) and demonstrate that AT 1 receptor activation is necessary for the full NF-B activation produced by LPS.
It is well established that administration of LPS elevates the gene expression of CD14, which is necessary for LPS recognition (46, 49) . We did not find significant changes in CD14 protein content after LPS administration, reflecting a possible difference in the time-dependent effects of LPS on CD14 transcription and translation. We report here that treatment with the ARB not only significantly prevented the LPS-induced increase in CD14 transcription in the spleen, but it also reduced basal CD14 protein expression. Our observations indicate that basal CD14 transcription is partially under control of AT 1 receptor activity and that AT 1 receptors are important for the LPS-induced activation of CD14 transcription. This suggests that the AT 1 receptor might be associated with the molecular mechanisms for LPS recognition. In the same context, the prevention of the LPS-induced upregulation of CD14 transcription may be an important mechanism by which ARBs impair the inflammatory response to LPS. Such AT 1 receptor-CD14 association, if present, is organ specific. In the adrenal gland, LPS administration also enhances CD14 transcription, but pretreatment with the ARB candesartan does not modify the LPS effect in this tissue (39) . On the other hand, there is no influence of LPS administration or ARB pretreatment on transcription of the LPS receptor TLR4 in the spleen, as reported here. However, LPS reduces TLR4 mRNA expression in the adrenal gland, an effect not modified by ARB pretreatment (39) . The extent to which the AT 1 receptor is important for LPS recognition and the effects in different organs remain to be determined.
Our study is not without limitations. Further studies will address the ARB effects on higher doses and chronic administration of the endotoxin, alterations of the immune response over time, and the specific cellular targets of these effects. The innate immune response is essential for eliminating pathogens and preparing for the transfer to the more specific, acquired immune response (5) . Whether the reduction in inflammation as a consequence of ARB administration is therapeutically useful is not known. However, an exaggerated innate immune response can lead to chronic inflammation and loss of homeostasis (23) . In addition, we previously showed that ARBs prevent the development of life-threatening gastric ulcers induced by cold restraint, by limiting the massive inflammatory response of the gastric mucosa (7). Therefore, limiting and controlling the innate immune response may be therapeutic.
Perspectives and Significance
It is clearly established that ARBs not only reduce blood pressure in hypertension, but they also reverse the vascular inflammation and endothelial dysfunction characteristic of this disease (9, 40) ; it has also been proved that anti-inflammatory effects of ARBs extend beyond the effects of ARBs on hypertension. Examples of the latter are as follows: prevention of stress-induced inflammation of the gastric mucosa (7); decrease of the inflammatory response to LPS in the adrenal gland (39) and spleen (present results) in normotensive animals; reduction of the eye inflammatory reaction in LPSinduced uveitis (28) and choroidal neovascularization (30) models; and decrease of inflammation in leukocytes from normal subjects (10) . Safe and well-tolerated drugs that limit the inflammatory reaction are important, since excessive and uncontrolled responses lead to chronic inflammatory and degenerative diseases (5) . On the basis of our observations and those in the literature, we suggest that the significant antiinflammatory effects of candesartan and other ARBs not only contribute to its therapeutic efficacy in hypertension but may also be beneficial in other inflammatory disorders.
